Cytocom gets FDA nod for phase 2 trial of Covid drug candidate CYTO-205

TAGS

Cytocom has secured clearance from the US Food and Drug Administration (FDA) to undertake a phase 2 clinical trial of CYTO-205 for the treatment of Covid-19.

The company’s investigational new drug (IND) application for the mid-stage trial has been cleared by the FDA, paving way for Cytocom to assess the safety and efficacy of CYTO-205 in slowing or halting the progression of the SARS-CoV-2 virus.

According to Cytocom, CYTO-205 is designed to modulate the function of the immune system, reduce elevated inflammatory responses related to viral infection and block viral replication in human lung cells.

See also  Janssen secures DARZALEX FASPRO FDA approval for AL amyloidosis

The randomized phase 2 trial of CYTO-205 is anticipated to start patient enrollment during Q2 2021 at Loma Linda University Health in Loma Linda, California.

Michael Handley – President and CEO of Cytocom said: “Even as new vaccines are introduced into the market and inoculation programs continue to expand, the need for safe and effective therapies to treat COVID-19 remains undiminished, especially in light of the spread of new, highly contagious variants of the virus.

See also  Dr. Reddy’s, Senores launch Ketorolac Tromethamine Tablets in US

“The early data regarding the potential of CYTO-205, as both an interventional therapy and a preventative agent is compelling, and we look forward to working with investigators at Loma Linda to further explore the possibilities.”

Cytocom gets FDA nod for phase 2 trial of Covid drug candidate CYTO-205

Cytocom gets FDA nod for phase 2 trial of Covid drug candidate CYTO-205. Photo courtesy of fernando zhiminaicela from Pixabay.

The double-blind, placebo-controlled phase 2 study of CYTO-205 will enroll a maximum of 75 patients aged 18 years or more who have tested Covid positive, show symptoms of mild infection, and are at high risk for disease progression.

See also  Selpercatinib FDA approval : Lilly's therapy approved for treatment of lung and thyroid cancers with RET alteration

After getting either a placebo or CYTO-205, patients will be observed for 30 days to determine how many cases progress to a more severe stage of Covid-19.

Cytocom said that preclinical in vitro studies using the 229E coronavirus strain and the SARS-CoV-2 pathological corona virus strain have shown the potential of CYTO-205 in blocking the replication of corona viruses in human lung cells.

Previously generated data also indicate that CYTO-205 can thwart the life-threatening lung inflammation resulting from Covid-19, and also reduce the risk of reinfection, said the clinical stage biopharma company.

CATEGORIES
TAGS
Share This